Esonadogene imvoparvovec

依哌艾多基

Report date: 2026/03/24 20:00:35

Base Information

Drug NameEsonadogene imvoparvovec
Drug Alias NameRecombinant-adeno-associated-virus-NADH-dehydrogenase-subunit-4Opvika纽惟佳rAAV2-ND4NR-082 +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionMT-ND4 gene transference
TargetsNADH-ubiquinone oxidoreductase chain 4
Therapy Area/IndicationsOptic Atrophy, Hereditary, Leber
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesWuhan Neurophth Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHuazhong University Of Science And TechnologyNewforth (Suzhou) Biotechnology Co LtdWuhan Neurophth Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOptic Atrophy, Hereditary, Leber
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A